Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04214639 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 183
- Enrollment target
- 13
- Study locations
NCT04214639: Completed Phase 3 study of Acne Vulgaris, sponsored by Bausch Health Americas.
NCT04214639 is a Phase 3 study of Acne Vulgaris that has completed, run by Bausch Health Americas. The registered enrollment target is 183 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (33% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04214639, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 183 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
Conditions Studied
Interventions
- DRUG IDP-126 Gel
- DRUG IDP-126 Vehicle Gel
Study Locations (13)
Florida
- Bausch Site 102 - Boynton Beach
- Bausch Site 111 - North Miami Beach
- Bausch Site 106 - Sanford
Ontario
- Bausch Site 101 - Barrie
- Bausch Site 113 - Waterloo
Arkansas
- Bausch Site 110 - Bryant
California
- Bausch Site 104 - Fremont
Colorado
- Bausch Site 109 - Denver
Nevada
- Bausch Site 103 - Las Vegas
New York
- Bausch Site 114 - New York
North Carolina
- Bausch Site 105 - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2021-01-18 |
| Phase | Phase 3 |
What the finished NCT04214639 record still lists
NCT04214639 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which IDP-126 Gel is the first listed.
NCT04214639 lists 13 locations in 10 states (Florida, Ontario, Arkansas).
Frequently Asked Questions
What is clinical trial NCT04214639 about?
NCT04214639 is a clinical study titled "Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris". This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
What is the current status of trial NCT04214639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2020-01-17. Estimated completion is 2021-01-18.
What conditions does trial NCT04214639 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04214639?
The interventions under investigation include: IDP-126 Gel (DRUG), IDP-126 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT04214639?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04214639 being conducted?
This trial has 13 study locations across Arkansas, California, Colorado, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04214639's enrollment target sits among peer trials
183 31st of 67 higher than 37 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI